Repositioning Candidate Details
| Candidate ID: | R0147 |
| Source ID: | DB00439 |
| Source Type: | approved; withdrawn |
| Compound Type: | small molecule |
| Compound Name: | Cerivastatin |
| Synonyms: | Cerivastatin |
| Molecular Formula: | C26H34FNO5 |
| SMILES: | COCC1=C(C2=CC=C(F)C=C2)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C(C(C)C)N=C1C(C)C |
| Structure: |
|
| DrugBank Description: | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market. |
| CAS Number: | 145599-86-6 |
| Molecular Weight: | 459.5503 |
| DrugBank Indication: | Used as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate. |
| DrugBank Pharmacology: | Cerivastatin, a competitive HMG-CoA reductase inhibitor effective in lowering LDL cholesterol and triglycerides, is used to treat primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb). |
| DrugBank MoA: | Cerivastatin competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the hepatic enzyme responsible for converting HMG-CoA to mevalonate. As mevalonate is a precursor of sterols such as cholesterol, this results in a decrease in cholesterol in hepatic cells, upregulation of LDL-receptors, and an increase in hepatic uptake of LDL-cholesterol from the circulation. |
| Targets: | 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor |
| Inclusion Criteria: | Target associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|